Stay updated on Pembrolizumab for HNSCC Residual Disease Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for HNSCC Residual Disease Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for HNSCC Residual Disease Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    Revision: v3.5.2 is now shown in the page footer, replacing Revision: v3.5.0. No changes to study content or data are indicated.
    Difference
    0.1%
    Check dated 2026-04-16T11:09:55.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    Added the disease term 'Squamous cell carcinoma of the head and neck' and a Resources entry for Genetic and Rare Diseases Information Center.
    Difference
    0.2%
    Check dated 2026-04-02T05:35:51.000Z thumbnail image
  4. Check
    35 days ago
    Change Detected
    Summary
    Revision: v3.5.0 added and Revision: v3.4.3 removed. This appears to be a technical site update with no changes to trial content.
    Difference
    0.1%
    Check dated 2026-03-18T20:19:27.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3.
    Difference
    0.1%
    Check dated 2026-03-11T18:23:08.000Z thumbnail image
  6. Check
    71 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2. Deleted the government funding lapse notice and related operating-status information (Revision: v3.4.1).
    Difference
    0.4%
    Check dated 2026-02-11T10:20:06.000Z thumbnail image
  7. Check
    78 days ago
    Change Detected
    Summary
    Added a site-wide notice about funding-related status and updated the page revision from v3.4.0 to v3.4.1.
    Difference
    0.4%
    Check dated 2026-02-04T06:39:26.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for HNSCC Residual Disease Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for HNSCC Residual Disease Clinical Trial page.